The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Effects of statins on mitochondrial pathways
Open accessAbstract
Statins are a family of drugs that are used for treating hyperlipidaemia with a recognized capacity to prevent cardiovascular disease events. They inhibit β‐hydroxy β‐methylglutaryl‐coenzyme A reductase, i.e. the rate‐limiting enzyme in mevalonate pathway, reduce endogenous cholesterol synthesis, and increase low‐density lipoprotein clearance by promoting low‐density lipoprotein receptor expression mainly in the hepatocytes. Statins have pleiotropic effects including stabilization of atherosclerotic plaques, immunomodulation, anti‐inflammatory properties, improvement of endothelial function, antioxidant, and anti‐thrombotic action. Despite all beneficial effects, statins may elicit adverse reactions such as myopathy. Studies have shown that mitochondria play an important role in statin‐induced myopathies. In this review, we aim to report the mechanisms of action of statins on mitochondrial function. Results have shown that statins have several effects on mitochondria including reduction of coenzyme Q10 level, inhibition of respiratory chain complexes, induction of mitochondrial apoptosis, dysregulation of Ca 2+ metabolism, and carnitine palmitoyltransferase‐2 expression. The use of statins has been associated with the onset of additional pathological conditions like diabetes and dementia as a result of interference with mitochondrial pathways by various mechanisms, such as reduction in mitochondrial oxidative phosphorylation, increase in oxidative stress, decrease in uncoupling protein 3 concentration, and interference in amyloid‐β metabolism. Overall, data reported in this review suggest that statins may have major effects on mitochondrial function, and some of their adverse effects might be mediated through mitochondrial pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Forouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Mitochondria, oxygen free radicals, disease and ageing
Raha, S., & Robinson, B. H. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01674-1 · Cited by 1,066
Statins: mechanism of action and effects
Stancu, C., & Sima, A. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00172.x · Cited by 911 · cited 2×
“of isoprenoids compounds, such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate, as a consequence of the blockade on the mevalonate pathway.(14) Protein farnesylation”
BackgroundCarnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects
BONNEFONT, J. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.06.004 · Cited by 637 · cited 1×
“Laboratory tests display high plasma acylcarnitine levels and acylcarnitine/carnitine ratio.(125) Such”
BackgroundStatin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000231980 · Cited by 557
Effect of statins on skeletal muscle function
Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.136101 · Cited by 500 · cited 1×
“manifestations, such as myalgia, weakness, tendon pain, night muscle cramping, and rhabdomyolysis in most severe cases.(41,42) Weakness and pain usually involve large back muscles and proximal muscle groups symmetrically.”
BackgroundStatins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Mitochondrial H + Leak and ROS Generation: An Odd Couple
Brookes, P. S. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.10.016 · Cited by 447
Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439 · cited 1×
“CVD risk is reduced by ~22% per each 1 mmol/L LDL cholesterol decrease.(3) There is overwhelming evidence showing an increasing clinical benefit when greater and earlier LDL cholesterol reductions are achieved.”
BackgroundFerence, B. A., Majeed, F., Penumetcha, R., Flack, J. M., & Brook, R. D. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.020 · Cited by 407
Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis
Mann, D. M., Woodward, M., Muntner, P., Falzon, L., & Kronish, I. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p150 · Cited by 329
DE PINIEUX, G., CHARIOT, P., AMMI‐SAÏD, M., LOUARN, F., LEJONC, J. L., ASTIER, A., JACOTOT, B., & GHERARDI, R. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.04178.x · Cited by 262 · cited 1×
“, Murlasists and Radák, and Herminghaus et al.(58,95,96) Inhibition of complex IV Myopathy Phillips et al.”
BackgroundBouitbir, J., Charles, A.-L., Echaniz-Laguna, A., Kindo, M., Daussin, F., Auwerx, J., Piquard, F., Geny, B., & Zoll, J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr224 · Cited by 256 · cited 5×
“The differential response in terms of mitochondrial biogenesis according to ROS production is known as mitochondrial hormesis and can explain why some tissues and cells, in particular fast muscle fibres, are more susceptible to statin toxicity.(70) It is notable that PGC‐1β knockout mice showed mitochondrial dysfuncti…”
BackgroundInfluentialGenetic risk factors associated with lipid-lowering drug-induced myopathies
Vladutiu, G. D., Simmons, Z., Isackson, P. J., Tarnopolsky, M., Peltier, W. L., Barboi, A. C., Sripathi, N., Wortmann, R. L., & Phillips, P. S. (2006) · Muscle & Nerve · doi:10.1002/mus.20567 · Cited by 253
Müller, W. E., Eckert, A., Kurz, C., Eckert, G. P., & Leuner, K. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8141-5 · Cited by 243
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
Mangravite, L. M., Engelhardt, B. E., Medina, M. W., Smith, J. D., Brown, C. D., Chasman, D. I., Mecham, B. H., Howie, B., Shim, H., Naidoo, D., et al. (2013) · Nature · doi:10.1038/nature12508 · Cited by 224
How do we improve patient compliance and adherence to long-term statin therapy?
Maningat, P., Gordon, B. R., & Breslow, J. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0291-7 · Cited by 208
Effects of Coenzyme Q10 on Statin-Induced Myopathy
Banach, M., Serban, C., Sahebkar, A., Ursoniu, S., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Glasser, S. P., et al. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.08.021 · Cited by 198 · cited 3×
“In fact, subclinical genetic mutations or polymorphisms have been associated with higher risk of SAS and SAMS.114 Polymorphisms on gene COQ2, encoding for an enzyme involved in endogenous ubiquinone biosynthesis, have been associated to SAS and SAMS.115 Similar findings have been reported for ATP2B1, encoding for a ca…”
BackgroundInfluentialSelf-citationQu, H., Guo, M., Chai, H., Wang, W., Gao, Z., & Shi, D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009835 · Cited by 178 · cited 3×
“In fact, subclinical genetic mutations or polymorphisms have been associated with higher risk of SAS and SAMS.114 Polymorphisms on gene COQ2, encoding for an enzyme involved in endogenous ubiquinone biosynthesis, have been associated to SAS and SAMS.115 Similar findings have been reported for ATP2B1, encoding for a ca…”
BackgroundInfluentialMuscle coenzyme Q10 level in statin-related myopathy
Lamperti, C., Naini, A. B., Lucchini, V., Prelle, A., Bresolin, N., Moggio, M., Sciacco, M., Kaufmann, P., & DiMauro, S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1709 · Cited by 178
Laaksonen, R., Jokelainen, K., Sahi, T., Tikkanen, M. J., & Himberg, J.-J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90266-x · Cited by 177
Laaksonen, R., Jokelainen, K., Laakso, J., Sahi, T., Härkönen, M., Tikkanen, M. J., & Himberg, J.-J. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89180-1 · Cited by 171
Simvastatin Effects on Skeletal Muscle
Larsen, S., Stride, N., Hey-Mogensen, M., Hansen, C. N., Bang, L. E., Bundgaard, H., Nielsen, L. B., Helge, J. W., & Dela, F. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.036 · Cited by 165
Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle
Sirvent, P., Mercier, J., Vassort, G., & Lacampagne, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.070 · Cited by 154
Simvastatin induces impairment in skeletal muscle while heart is protected
Sirvent, P., Bordenave, S., Vermaelen, M., Roels, B., Vassort, G., Mercier, J., Raynaud, E., & Lacampagne, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.108 · Cited by 116
Kwak, H.-B., Thalacker-Mercer, A., Anderson, E. J., Lin, C.-T., Kane, D. A., Lee, N.-S., Cortright, R. N., Bamman, M. M., & Neufer, P. D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.449 · Cited by 114
Uncoupling protein 3 content is decreased in skeletal muscle of patients with type 2 diabetes
Schrauwen, P., Hesselink, M. K. C., Blaak, E. E., Borghouts, L. B., Schaart, G., Saris, W. H. M., & Keizer, H. A. (2001) · Diabetes · doi:10.2337/diabetes.50.12.2870 · Cited by 112
Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin
Schick, B. A., Laaksonen, R., Frohlich, J. J., Päivä, H., Lehtimäki, T., Humphries, K. H., & Côté, H. C. F. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100124 · Cited by 103
Pirro, M., Vetrani, C., Bianchi, C., Mannarino, M. R., Bernini, F., & Rivellese, A. A. (2017) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.11.122 · Cited by 99
Self-citationMuscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins
Sirvent, P., Fabre, O., Bordenave, S., Hillaire-Buys, D., Raynaud De Mauverger, E., Lacampagne, A., & Mercier, J. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.01.008 · Cited by 90
Wu, J. S., Buettner, C., Smithline, H., Ngo, L. H., & Greenman, R. L. (2011) · Muscle & Nerve · doi:10.1002/mus.21847 · Cited by 61
Clinical characterization and molecular mechanisms of statin myopathy
Toth, P. P., Harper, C. R., & Jacobson, T. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.7.955 · Cited by 55 · cited 1×
“Underlying these manifestations is a statin‐induced myopathy (SIM), whose pathophysiology has not been fully understood yet.(44)”
BackgroundGATM gene variants and statin myopathy risk
Carr, D. F., Alfirevic, A., Johnson, R., Chinoy, H., van Staa, T., & Pirmohamed, M. (2014) · Nature · doi:10.1038/nature13628 · Cited by 35
Cited by
Mølmen, K. S., Almquist, N. W., & Skattebo, Ø. (2025) · Sports Medicine · doi:10.1007/s40279-024-02120-2 · Cited by 123
Garrahy, J. P. (2025) · Journal of Alzheimer’s Disease · doi:10.1177/13872877251350338 · Cited by 6
Metadata
- Authors
- Mollazadeh, H., Tavana, E., Fanni, G., Bo, S., Banach, M., Pirro, M., von Haehling, S., Jamialahmadi, T., & Sahebkar, A.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2021-01-29
- Volume
- 12
- Issue
- 2
- Pages
- 237-251
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W3125158701
- Cited by
- 249
- References
- 41
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.